RIVIERA BEACH, Fla.,
May 19, 2017 /PRNewswire/ -- Sancilio
& Company, Inc. (SCI) announced the participation of members of
the leadership and scientific team at the Scientific Sessions of
the National Lipid Association (NLA) on May
20th, 2017, in Philadelphia,
PA, where they will deliver several novel scientific
presentations from the company's current research.
The key findings from the research presented in this meeting,
using Advanced Lipid Technologies™ (ALT®), further support enhanced
bioavailability, overcoming food effect, and reduction of
triglyceride levels after patients were treated with omega-3 fatty
acids + ALT®. These presentations will update the research
community on the clinical work being performed at SCI, in support
of SCI's late-stage development program, SC401, in Severe
Hypertriglyceridemia.
"We are excited to share these data at such an important
scientific event," said Dr. Frederick D.
Sancilio, PhD, President and CEO of SCI.
The following poster presentations are scheduled to be delivered
Saturday, May 20th, 2017:
- Abstract 193: A Novel Omega‐3‐Acid Ethyl Ester Formulation
Incorporating Advanced Lipid Technologies™
(ALT®) Improves DHA and EPA bioavailability compared with
Lovaza. Lopez-Toledano, MA; Thorsteinsson, T; Daak, AA; Maki,
KC; Johns, C; Rabinowicz, AL and Sancilio, F.
- Abstract 192: Minimal Food Effect for Eicosapentaenoic Acid
and Docosahexaenoic Acid Bioavailability from Omega‐3 Acid Ethyl
Esters with an ALT® based formulation. Lopez-Toledano, MA;
Thorsteinsson, T; Daak, AA; Maki, KC; Johns, C; Rabinowicz, AL and
Sancilio, F.
- Abstract 191: Triglyceride‐lowering Effect of Omega‐3 Fatty
Acid Ethyl Esters Using Advanced Lipid
Technologies™ (ALT®) formulations under
fasting conditions. Lopez-Toledano MA, Daak, AA, Thorsteinsson,
T, Sancilio, F and Rabinowicz AL.
The NLA is a nonprofit multidisciplinary health care community
that focuses on the prevention of dyslipemias and their associated
cardiometabolic disorders. Its mission is to enhance the practice
of lipid management in clinical medicine and enhance the efforts to
reduce death and disability related to disorders of lipid
metabolism in patients.
About Sancilio & Company, Inc.
Sancilio & Company, Inc. (SCI) is a fully integrated,
specialty pharmaceutical company focused on developing,
manufacturing and commercializing pharmaceutical products,
including those based on our proprietary Advanced Lipid
Technologies™ (ALT®) platform. SCI is pursuing treatments for
sickle cell disease, short bowel syndrome and severe
hypertriglyceridemia. We utilize our cGMP compliant facility
to develop and manufacture our products. Our ALT® platform is
designed to enhance the bioavailability, reduce the food effect and
improve the efficacy of lipids and lipophilic active pharmaceutical
ingredients (APIs). Our business model is to apply our ALT®
platform to lipids or lipophilic APIs to create unique product
candidates that address the disorders and diseases resulting from
imbalances of lipids in the body. In addition to our primary focus
of developing our proprietary products using the ALT® platform, we
make use of, and license rights to, our proprietary ALT® platform
and other technologies to third parties, providing both development
and subsequent soft gelatin encapsulation services as
required. More information is available at:
www.sancilio.com.
Related Links
About SC411
sancilio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sancilio--company-inc-presents-novel-research-at-the-15th-anniversary-scientific-sessions-of-the-national-lipid-association-nla-300460918.html
SOURCE Sancilio & Company, Inc.